<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Wang Y</submitter><funding>National Natural Science Foundation of China</funding><pubmed_abstract>It is of great significance to design and synthesize novel structural inhibitors with good antitumor activity. In this study, based on rational design, a total of 42 7-azaindole derivatives as novel CDK8 inhibitors were designed and synthesized. All compounds were screened with antitumor activity and compound 6 (1-(3-((1&lt;i>H&lt;/i>-pyrrolo[2,3-&lt;i>b&lt;/i>]pyridin-5-yl)oxy)phenyl)-3-(&lt;i>m&lt;/i>-tolyl)urea) exhibited the best activity, especially in acute myeloid leukemia (GI&lt;sub>50&lt;/sub> MV4-11 = 1.97 ± 1.24 μM). This compound also exhibited excellent inhibitory activity against CDK8 (IC&lt;sub>50&lt;/sub> = 51.3 ± 4.6 nM). Further mechanism studies shown that it could inhibit STAT5 phosphorylation and induce cell cycle arrest in the G1 phase, leading to apoptosis in acute myeloid leukemia cells. In addi</pubmed_abstract><journal>RSC medicinal chemistry</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11325196</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Design and synthesis of 7-azaindole derivatives as potent CDK8 inhibitors for the treatment of acute myeloid leukemia.</pubmed_title><pmcid>PMC11325196</pmcid><funding_grant_id>22377001</funding_grant_id><funding_grant_id>21977001</funding_grant_id><pubmed_authors>Liu X</pubmed_authors><pubmed_authors>Zhi L</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Lei C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Design and synthesis of 7-azaindole derivatives as potent CDK8 inhibitors for the treatment of acute myeloid leukemia.</name><description>It is of great significance to design and synthesize novel structural inhibitors with good antitumor activity. In this study, based on rational design, a total of 42 7-azaindole derivatives as novel CDK8 inhibitors were designed and synthesized. All compounds were screened with antitumor activity and compound 6 (1-(3-((1&lt;i>H&lt;/i>-pyrrolo[2,3-&lt;i>b&lt;/i>]pyridin-5-yl)oxy)phenyl)-3-(&lt;i>m&lt;/i>-tolyl)urea) exhibited the best activity, especially in acute myeloid leukemia (GI&lt;sub>50&lt;/sub> MV4-11 = 1.97 ± 1.24 μM). This compound also exhibited excellent inhibitory activity against CDK8 (IC&lt;sub>50&lt;/sub> = 51.3 ± 4.6 nM). Further mechanism studies shown that it could inhibit STAT5 phosphorylation and induce cell cycle arrest in the G1 phase, leading to apoptosis in acute myeloid leukemia cells. In addi</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2026-06-02T09:15:55.988Z</modification><creation>2024-12-03T19:35:55.121Z</creation></dates><accession>S-EPMC11325196</accession><cross_references><pubmed>39157854</pubmed><doi>10.1039/d4md00465e</doi></cross_references></HashMap>